Edwards Lifesciences Gestion

Gestion contrôle des critères 2/4

Le PDG Edwards Lifesciences est Bernard Zovighian, nommé en May2023, a un mandat de 1.5 ans. La rémunération annuelle totale est $ 12.87M, composée du salaire de 7.6% et des bonus 92.4%, y compris les actions et options de la société. détient directement 0.012% des actions de la société, d'une valeur de € 4.84M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.2 ans et 4.5 ans.

Informations clés

Bernard Zovighian

Directeur général

US$12.9m

Rémunération totale

Pourcentage du salaire du PDG	7.6%
Durée du mandat du directeur général	1.5yrs
Propriété du PDG	0.01%
Durée moyenne d'occupation des postes de direction	5.2yrs
Durée moyenne du mandat des membres du conseil d'administration	4.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Bernard Zovighian a-t-elle évolué par rapport aux bénéfices de Edwards Lifesciences?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$13m	US$973k	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$3m	US$642k	US$2b

Rémunération vs marché: La rémunération totale de Bernard ($USD 12.87M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Austrian ($USD 4.35M ).

Rémunération et revenus: La rémunération de Bernard a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Bernard Zovighian (56 yo)

1.5yrs

Titularisation

US$12,869,020

Compensation

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Bernard Zovighian	CEO & Director	1.5yrs	US$12.87m	0.012% € 4.8m
Scott Ullem	Corporate VP & CFO	10.8yrs	US$5.95m	0.046% € 18.5m
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	8.8yrs	US$4.29m	0.035% € 14.0m
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	1.8yrs	US$5.40m	0.030% € 12.1m
Andrew Dahl	Principal Accounting Officer	less than a year	pas de données	0.00030% € 119.8k
Todd Brinton	Corporate VP of Advanced Technology & Chief Scientific Officer	5.8yrs	pas de données	pas de données
Mark Wilterding	Vice President of Investor Relations	no data	pas de données	pas de données
Arnold Pinkston	Corporate VP & General Counsel	5.2yrs	pas de données	pas de données
Dirksen Lehman	Corporate Vice President of Public Affairs	11.4yrs	pas de données	pas de données
Christine McCauley	Corporate Vice President of Human Resources	12.3yrs	pas de données	pas de données
Gary Sorsher	Senior Vice President of Quality & Regulatory Compliance	1.3yrs	pas de données	pas de données
Wayne Markowitz	GM & Senior VP of Surgical Structural Heart	1.3yrs	pas de données	0.00021% € 83.8k

5.2yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de EWLS est chevronnée et expérimentée (5.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Bernard Zovighian	CEO & Director	1.5yrs	US$12.87m	0.012% € 4.8m
Kieran Gallahue	Independent Director	9.8yrs	US$335.06k	0.012% € 4.9m
Paul LaViolette	Independent Director	4.3yrs	US$329.97k	0.0013% € 522.9k
Steven Loranger	Independent Director	8.7yrs	US$335.06k	0.012% € 4.8m
Leslie Heisz	Independent Director	8.3yrs	US$356.42k	0.0046% € 1.8m
Nicholas Valeriani	Independent Chairman	10yrs	US$347.97k	0.012% € 4.7m
Leslie Davis	Independent Director	less than a year	pas de données	pas de données
David Feinberg	Director	less than a year	pas de données	pas de données
Ramona Sequeira	Independent Director	4.5yrs	US$334.97k	0.0019% € 746.5k

4.5yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EWLS sont considérés comme expérimentés (ancienneté moyenne 4.5 ans).

Edwards Lifesciences Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Insufficient new directors

Insider recently sold €453k worth of stock

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Insider recently sold €101k worth of stock

Insider recently sold €846k worth of stock

Recent updates

Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Edwards Lifesciences Announces Results from the EARLY TAVR Trial

Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.63 in 3Q 2023)

Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024

Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Now 21% undervalued after recent price drop

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.61 (vs US$0.51 in 2Q 2023)

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.56 in 1Q 2023)

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Full year 2023 earnings released: EPS: US$2.31 (vs US$2.46 in FY 2022)

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Investor sentiment improves as stock rises 17%

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

New minor risk - Share price stability

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Now 22% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.63 (vs US$0.55 in 3Q 2022)

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Insufficient new directors

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.66 in 2Q 2022)

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Insider recently sold €453k worth of stock

First quarter 2023 earnings released: EPS: US$0.56 (vs US$0.60 in 1Q 2022)

Full year 2022 earnings released: EPS: US$2.46 (vs US$2.41 in FY 2021)

Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.55 in 3Q 2021)

Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022

Edwards Lifesciences Corporation Announces Results from CLASP IID

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval

Insider recently sold €101k worth of stock

Second quarter 2022 earnings released: EPS: US$0.66 (vs US$0.79 in 2Q 2021)

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022

Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022

Insider recently sold €846k worth of stock

Insider recently sold €49k worth of stock

First quarter 2022 earnings released: EPS: US$0.60 (vs US$0.54 in 1Q 2021)

Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022